Objective: Inflammation in adipose tissue may link obesity to insulin resistance and atherosclerosis. Arachidonate 5-lipoxygenase activating protein (ALOX5AP) gene is involved in the pathogenesis of atherosclerotic cardiovascular disease (CVD). We investigated ALOX5AP expression in adipose tissue, and association of gene polymorphisms with obesity and insulin resistance. Design: For gene expression analysis in adipose tissue, we studied 12 lean and 36 obese women, eight lean and 13 obese men, and nine women before and 2-4 years after gastric banding surgery. For genetic analysis, we studied 231 nonobese and 350 obese men. Results: The ALOX5AP protein, 5-lipoxygenase activating protein (FLAP), as well as 5-lipoxygenase (5LO) itself, were detected in adipocytes. The mRNA expression of ALOX5AP in subcutaneous adipose tissue was increased in obesity and normalized following weight reduction. High adipose tissue mRNA expression of ALOX5AP is associated with insulin resistance as measured by homeostasis model assessment (HOMA IR ). ALOX5AP haplotypes that associate with CVD are not associated with obesity or insulin resistance. Conclusion: ALOX5AP is present in adipose tissue, where its expression is associated with body weight and HOMA IR , and may provide a link between adipose tissue, inflammation and insulin resistance. Investigated ALOX5AP haplotypes are not major primary risk factors for obesity and insulin resistance.
Introduction
Obesity, insulin resistance, type 2 diabetes, and atherosclerotic cardiovascular disease (CVD) are closely associated and may have inflammation as a common denominator. Inflammation plays an important role in the development of CVD.
1,2 A low-grade inflammation is often present in insulinresistant states such as obesity and predict type 2 diabetes. 3, 4 The low-grade inflammation of obesity is characterized by macrophage infiltration and increased expression of inflammatory genes in adipose tissue of humans and mice, and this inflammation may play an important role for obesity-related insulin resistance. 5, 6 Through secretion of proinflammatory factors into the circulation, adipose tissue inflammation can have systemic effects. 7 However, the details of adipose tissue inflammation; the factor/s that recruit macrophages, as well as key molecules and pathways that cause insulin resistance are poorly understood. A preliminary analysis of the profile of gene expression in adipose tissue demonstrated that ALOX5AP mRNA is expressed in human subcutaneous adipose tissue (unpublished). ALOX5AP encodes the protein 5-lipoxygenase activating protein (FLAP), which facilitates the initial step in leukotriene biosynthesis from arachidonic acid catalyzed by 5-lipoxygenase (5LO). 8 The most important product of this pathway is leukotriene B4 (LTB4). LTB4 is a ligand for peroxisome proliferator receptor alpha (PPARA), which has important roles in lipid metabolism, as well as peroxisome and mitochondrial beta-oxidation. 9, 10 Furthermore, LTB4 strongly induces monocyte chemoattractant protein 1 (MCP1) production in human monocytes. 11 MCP1 is increased in the circulation of obese subjects, is produced by adipose tissue, and decreases glucose uptake in adipocytes. [12] [13] [14] Both MCP1 and 5LO products recruit leukocytes to sites of inflammation. 15 These data indirectly suggest that ALOX5AP also might play a role in obesity. Recently, common haplotypes in the ALOX5AP gene were shown to confer risk of myocardial infarction and stroke, and to be associated with more leukotriene production in neutrophiles. 16 In the study by Helgadottir et al.
ALOX5AP
was shown to have a much stronger impact on CVD among men than women. Previously, FLAP has been reported to be primarily expressed in bone marrow-derived cells, and has been implicated in asthma and allergic disease (reviewed by Peters-Golden and Brock 17 ).
Based on the above functions ascribed to 5LO and FLAP, we hypothesize that these genes could have a role in obesity and insulin resistance. We therefore investigated 5LO and FLAP expression in the various cell types of human adipose tissue, studied the influence of obesity on ALOX5AP in this tissue, and explored whether the CVD-associated ALOX5AP haplotypes were associated with obesity and insulin resistance in Swedish men. For measuring mRNA and protein in different cell types of adipose tissue, subcutaneous adipose tissue was obtained in connection with abdominal liposuction because of cosmetic reasons. All subjects in whom mRNA was quantified were healthy.
Methods

Study subjects and clinical examination
All individuals came to the laboratory at 0800 after an overnight fast. Height, weight, and waist circumference were determined and a fasting venous blood sample was obtained for measurements of total cholesterol, HDL cholesterol, triglycerides, glucose, Insulin, and DNA extraction as described 19, 20 Insulin resistance index HOMA IR was calculated as fasting serum insulin (mU/ml) Â fasting Pl glucose (mmol/l)/22.5. 21 In methodological experiments on 60 subjects (BMI 18-50 kg/m 2 ), we found that HOMA IR correlated strongly with direct measurements of insulin sensitivity by the hyperinsulinemic, euglycemic clamp technique (r ¼ 0.83, Po0.001).
Needle biopsies of abdominal subcutaneous adipose tissue (1-2 g) were obtained under local anesthesia in the morning after an overnight fast. Adipose tissue was treated with collagenase as described for isolation of adipocytes. 22 Isolated fat cells and adipose tissue were immediately frozen in liquid nitrogen for subsequent RNA or protein analysis. Cells from the stroma vascular fraction were separated as described. 23 Adipose tissue-derived cells were homogenized in denaturing buffer from RNeasy kit (Qiagen, Courtaboeuf, France) and stored at À801C until RNA preparation. The local committee on ethics approved the project. It was explained in detail to each participant and informed consent was obtained.
RNA extraction and real time PCR
Total RNA was extracted from human adipose tissue and reverse transcribed as described. 24 Quantitative real-time PCR (RT-qPCR) was performed on an iCycler IQ (Bio-Rad Laboratories, Hercules, CA, USA). ALOX5AP was quantified using TaqMan (Hs00233463_m1, Applied Biosystems, Foster City, CA, USA) with 25 ng of cDNA used in triplicate 25 ml PCR reactions. SYBR Green-based technology was used for the internal control gene b-2 microglobulin (B2MG). The primer pairs for B2MG were designed to span exon-intron boundaries and generate a single amplicon according to dissociation curves and agarose gel electrophoresis. B2MG primers sequences were 5 0 -TGCTGTCTCCATGTTTGATG TATCT-3 0 and 5 0 -TCTCTGCTCCCCACCTCTAAGT-3 0 . A total of 8 ng of cDNA were used in triplicate 25 ml PCR reactions. In methodological experiments on cDNA from subcutaneous adipose tissue of 200 subjects, CT values for B2MG were not ALOX5AP and obesity M Kaaman et al related to BMI or HOMA IR . Expression of ALOX5AP was normalized to the B2MG internal control using the formula 2 (Ct ALOX5AP calibrator -Ct ALOX5AP sample)/2 (Ct B2MG calibrator -Ct B2MG sample), where calibrator is a random sample. Men and women were run on different time-points without controls permitting comparison between groups. For analysis of ALOX5AP mRNA expression in different cell types from adipose tissue, RT-qPCR was performed on a GeneAmp 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using Taqman technology as described above. 18S ribosomal RNA (Ribosomal RNA Control TaqMan Assay kit, Applied Biosystems, Foster City, CA, USA) was used in these experiments as control to normalize gene expression.
Western blot
Total protein was isolated from isolated adipocytes as described. 24 Lymphocyte protein was isolated as positive control. Protein (100 mg) was immunoprecipitated overnight at 41C with a polyclonal antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). Protein A Sepharose (Pharmacia, Uppsala, Sweden) was added the next day. The samples were boiled at 1001C for 7 min with SDS loading buffer containing b-mercaptoethanol and dithiothreitol (DTT), in order to optimize the reducing conditions. This procedure was made in line with Mandal et al. 25 where FLAP was found in dimeric and trimeric form. The samples where run on a 15% SDSpolyacryl gel, blotted onto a PVDF membrane and incubated with a polyclonal FLAP antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) or a polyclonal antibody against 5LO kindly donated by Dr Olof Rådmark. Proteins obtained from monocytes and recombinant 5LO (kindly donated by Dr Olof Rådmark at Karolinska Institutet, Stockholm, Sweden) were used as positive controls.
Genotyping
The seven ALOX5AP single nucleotide polymorphisms (SNPs) defining the two haplotypes previously associated with CVD in the Icelandic and British population, respectively, were genotyped by a homogeneous minisequencing assay with fluorescence polarization detection 26, 27 Primer details and reaction conditions are available from the authors. All assays were in Hardy-Weinberg equilibrium and genotyping accuracy, as determined by randomly retyping 10% of the subjects, was 100%. Haplotypes were inferred using SNPHAP (http://archimedes.well.ox.ac.uk/ pise/snphap-simple.html). 
Statistical analysis
Results
FLAP mRNA and protein are present in adipocytes
We demonstrate in fat obtained in connection with abdominal liposuction because of cosmetic reasons that ALOX5AP mRNA is expressed in all cell fractions of adipose tissue; 10-fold higher in the stroma vascular fraction than in isolated adipocytes (Po0.01), and 10-fold higher in infiltrating macrophages than the stroma vascular fraction, Table 1 . Furthermore, the ALOX5AP protein, FLAP, is present in human isolated fat cells (Figure 1 ). Distinct bands were detected at 54, 36, and 18 kDa in isolated fat cells and control cells, that is, lymphocytes, corresponding to published trimers, dimers, and monomers of FLAP. 25 In isolated fat cells, we also detected a protein band corresponding to 5-lipogyxenase ( Figure 1 ).
Association of ALOX5AP mRNA expression with obesity and HOMA IR We compared ALOX5AP mRNA expression between obese and lean subjects. Obese subjects expressed significantly We next divided the subjects into tertiles based on ALOX5AP mRNA expression. High expression of ALOX5AP mRNA was associated with higher HOMA IR independently of BMI in both women (P-valueo0.01) and men (P-value o0.05), Figure 2 .
Analysis of association between ALOX5AP alleles and obesity phenotypes We investigated whether ALOX5AP alleles are associated with obesity and associated metabolic disturbances in men. For this purpose, we genotyped 231 nonobese and 350 obese men for seven common SNPs defining two haplotypes previously shown to contribute to CVD. 16 Only men were studied since the association with CVD was much stronger in men than in women. As expected the obese men displayed more extensive insulin resistance syndrome phenotypes including high HOMA IR (7.476.6), low Pl-HDL cholesterol (1.170.3 mmol/l), and high Pl-triglycerides (2.171.2 mmol/l) as compared to nonobese men. Genotyping success rate for the SNP sg13s35 was 96%, for the other SNPs success rate was 499%. No SNP was associated with obesity (Table 2) or investigated quantitative traits including HOMA IR or Pl lipids (results not shown). SHPHAP inferred nine haplotypes with frequency 41% (Table 3 ). The haplotypes associated with CVD on Iceland and in a UK population were detected with frequencies 12 and 8%, respectively. No haplotype was associated with obesity or investigated quantitative traits (results not shown). Excluding subjects with diabetes, dyslipidemia, and hypertension had no impact on the results.
Discussion
ALOX5AP is the first identified gene that confers substantial population attributable risk for atherogenic CVD. 16 We demonstrate that both the ALOX5AP protein FLAP and 5LO are present in fat cells. However, the quantitative comparison of gene expression suggests that ALOX5AP levels are lower in adipocytes than in stroma vascular cells of adipose tissue, such as macrophages and endothelial cells. We show that increased gene expression of ALOX5AP in adipose tissue is associated with an insulin-resistance phenotype, which, in turn, is a risk factor for CVD. First, the expression of ALOX5AP was markedly upregulated in obesity. Second, subjects with high ALOX5AP mRNA level in Adipose ALOX5AP is probably a regulator of the insulin resistance phenotype among the obese and not a primary cause of obesity because mRNA levels for ALOX5AP were normalized after weight reduction. FLAP and 5LO protein in adipocytes, which catalyze the initial step in leukotriene synthesis from arachidonic acid, could potentially contribute to recruitment of the inflammatory cells observed in human and experimental obesity, which has been implicated in development of insulin resistance. 5, 6 Potential local effects of leukotrienes in adipose tissue include macrophage recruitment, nitric oxide synthesase (NOS) production, induction of MCP-1, 11 and IL6 production. 28 These effectors are implicated both in inducing local insulin resistance in the adipose tissue and could also, by secretion into the circulation or changing the secretory function of adipocytes, contribution to generalized insulin resistance and, ultimately, the development of CVD. Although we propose several mechanisms by which ALOX5AP in adipose tissue could contribute to insulin resistance and CVD, the CVD-associated ALOX5AP haplotypes are not associated with obesity, HOMA IR , or dyslipidemia in men. The CVD-associated haplotypes are observed with similar frequencies in the present and previous investigated populations. 16 This support that the haplotype structure is similar in studied populations. Furthermore, investigated obese subjects displayed a high frequency of insulin resistance as measured by HOMA IR . With this in mind, we conclude that the CVD-associated ALOX5AP haplotypes are not major primary causes of obesity and insulin resistance in men. A minor importance of the ALOX5AP haplotypes on these phenotypes cannot be excluded with our sample. Nor can we exclude an impact of other ALOX5AP polymorphisms on obesity and its metabolic complications, or an impact on these phenotypes in women. In summary, FLAP and 5LO protein are detected in adipocytes and other cells in human adipose tissue. ALOX5-AP can potentially contribute to recruitment of inflammatory cells, and is upregulated in obese and insulin resistance subjects, thus providing a link between adipose tissue, inflammation, and insulin resistance. The CVD-associated ALOX5AP haplotypes are not major primary risk factors for obesity and insulin resistance.
